Condition: Idiopathic Pulmonary Fibrosis(IPF) · Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.
The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.
This description comes directly from the study's public registry record.
Jinfu Xu · 86-21-62483180 · hdyyll@126.com
Always discuss trial participation with your own doctor first.
| Sichuan Provincial People's Hospital | Chengdu, China | Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, China | Recruiting |
| Hangzhou First People's Hospital | Hangzhou, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
| Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School | Nanjing, China | Recruiting |
| The Affiliated Hospital of Inner Mongolia Medical University | Neimeng, China | Recruiting |
| Dongfang Hospital Affiliated to Tongji University | Shanghai, China | Recruiting |
| Huadong Hospital Affiliated to Fudan University | Shanghai, China | Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, China | Recruiting |
| General Hospital of Tianjin Medical University | Tianjin, China | Recruiting |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, China | Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07121413